Luca Guarnera
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Luca Guarnera has a total of 395 co-authors. Here are the top co-authors by number of shared publications:
- Adriano Venditti
Department of Biomedicine and Prevention University of Rome Tor Vergata Rome Italy
15 shared publications - Maria Teresa Voso
Department of Biomedicine and Prevention University of Rome Tor Vergata Rome Italy
12 shared publications - Valeria Visconte
Department of Translational Hematology and Oncology Research, Taussig Cancer Institute, Cleveland Clinic, Cleveland, USA
12 shared publications - Maria Ilaria Del Principe
Hematology Unit, Medical Area Department, S. Eugenio Hospital (ASL Roma 2), 00144 Rome, Italy
10 shared publications Arianna Savi
Department of Clinical and Biological Sciences, University of Turin, Turin, Italy
9 shared publications- Carmelo Gurnari
Department of Biomedicine and Prevention University of Rome Tor Vergata Rome Italy
8 shared publications
Latest Publications
- Open Access
- 7 November 2026
- Published by Wiley in American Journal of Hematology
Distinct Consequences of BCOR and BCORL1 Mutations in Myeloid Neoplasms and Bone Marrow Failure
BCOR and BCORL1 (BCOR/L1 ) mutations are observed in both myeloid neoplasms (MN) and bone marrow failure syndromes (BMF), but their clinical significance may differ. We analyzed 11 340 patients and identified 418 BCOR/L1 ‐mutated patients, focusing on differences between MN and BMF. Compared with MN, BMF was associated with younger age, a higher frequency of normal karyotype, a greater proportion of missense mutations, and significantly lower variant allele frequencies (VAFs). We next compared BCOR/L1 ‐mutated cases with wild‐type cases. In MN, BCOR/L1 mutations were associated with older age, inferior survival, and a higher number of co‐occurring mutations, whereas in BMF, they were associated with a higher prevalence of PNH clones. Single‐cell DNA sequencing and VAF‐based analysis demonstrated that BCOR/L1 mutations were usually secondary in MN but primary events in BMF. Longitudinal sequencing revealed that BCOR/L1 ‐mutant clones often contracted or disappeared over time, even in progression, suggesting limited clonal fitness of BCOR/L1 mutations themselves; instead, progression was associated with increased mutational burden, particularly in RUNX1 . Prognostically, BCOR/L1 mutations were associated with inferior survival in MN, whereas in BMF they were not associated with prognosis and tended to correlate with a favorable response to immunosuppressive therapy. RNA‐sequencing analyses showed reduced BCOR/L1 expression in BMF, and BCOR knockout was associated with reduced HLA class I expression. Our findings suggest that BCOR/L1 mutations are secondary events in MN and co‐occurring mutations may influence disease progression and prognosis, whereas in BMF they appear to be ancestral events acquired independently of progression to MN, potentially through immune privilege‐related mechanisms.
- 7 November 2026
- Published by Wiley in American Journal of Hematology
Open AccessDistinct Consequences of BCOR and BCORL1 Mutations in Myeloid Neoplasms and Bone Marrow Failure
BCOR and BCORL1 (BCOR/L1 ) mutations are observed in both myeloid neoplasms (MN) and bone marrow failure syndromes (BMF), but their clinical significance may differ. We analyzed 11 340 patients and identified 418 BCOR/L1 ‐mutated patients, focusing on differences between MN and BMF. Compared with MN, BMF was associated with younger age, a higher frequency of normal karyotype, a greater proportion of missense mutations, and significantly lower variant allele frequencies (VAFs). We next compared BCOR/L1 ‐mutated cases with wild‐type cases. In MN, BCOR/L1 mutations were associated with older age, inferior survival, and a higher number of co‐occurring mutations, whereas in BMF, they were associated with a higher prevalence of PNH clones. Single‐cell DNA sequencing and VAF‐based analysis demonstrated that BCOR/L1 mutations were usually secondary in MN but primary events in BMF. Longitudinal sequencing revealed that BCOR/L1 ‐mutant clones often contracted or disappeared over time, even in progression, suggesting limited clonal fitness of BCOR/L1 mutations themselves; instead, progression was associated with increased mutational burden, particularly in RUNX1 . Prognostically, BCOR/L1 mutations were associated with inferior survival in MN, whereas in BMF they were not associated with prognosis and tended to correlate with a favorable response to immunosuppressive therapy. RNA‐sequencing analyses showed reduced BCOR/L1 expression in BMF, and BCOR knockout was associated with reduced HLA class I expression. Our findings suggest that BCOR/L1 mutations are secondary events in MN and co‐occurring mutations may influence disease progression and prognosis, whereas in BMF they appear to be ancestral events acquired independently of progression to MN, potentially through immune privilege‐related mechanisms.
- Open Access
- 1 October 2026
- Published by Elsevier in Blood Global Hematology
- Vol. 2 (4)
APL: from troubled waters to calmer seas
- 1 October 2026
- Published by Elsevier in Blood Global Hematology
- Vol. 2 (4)
Open AccessAPL: from troubled waters to calmer seas
- Open Access
- 1 September 2026
- Published by Springer Nature in Clinical and Experimental Medicine
Prognostic stratification in MDS/MPN syndromes other than CMML: an Italian multicenter real-world study
MDS/MPN syndromes comprise a heterogeneous group of myeloid neoplasms. While CMML has been extensively characterized, data on other MDS/MPN entities remain limited, particularly in real-world settings. We conducted a nationwide, multicenter retrospective study including adult patients with MDS/MPN syndromes other than CMML from 17 Italian centers. Patients were classified as MDS/MPN with SF3B1 mutation and thrombocytosis ( SF3B1 -T), atypical chronic myeloid leukemia/chronic neutrophilic leukemia (aCML/CNL), or MDS/MPN not otherwise specified (NOS). A total of 101 patients were included (median age 71 years). MDS/MPN SF3B1 -T showed a significant survival advantage compared with MDS/MPN NOS and aCML/CNL (OS p = 0.0058, LFS p = 0.012). aCML/CNL displayed the worst outcomes and most genetic complexity. Across the overall cohort, IPSS-M demonstrated the highest discriminative ability and calibration accuracy for both OS and LFS, outperforming CMML-directed models, including BLAST-clinical and BLAST-molecular whereas disease-specific scores provided optimal stratification within individual entities but failed to adequately predict outcomes in MDS/MPN NOS. In this real-world analysis, IPSS-M emerged as the most robust prognostic framework across MDS/MPN entities other than CMML. The inability of current tools to reliably stratify patients with MDS/MPN NOS underscores the biological heterogeneity of this category and highlights the urgent need for integrated clinical and genomic prognostic models.
- 1 September 2026
- Published by Springer Nature in Clinical and Experimental Medicine
Open AccessPrognostic stratification in MDS/MPN syndromes other than CMML: an Italian multicenter real-world study
MDS/MPN syndromes comprise a heterogeneous group of myeloid neoplasms. While CMML has been extensively characterized, data on other MDS/MPN entities remain limited, particularly in real-world settings. We conducted a nationwide, multicenter retrospective study including adult patients with MDS/MPN syndromes other than CMML from 17 Italian centers. Patients were classified as MDS/MPN with SF3B1 mutation and thrombocytosis ( SF3B1 -T), atypical chronic myeloid leukemia/chronic neutrophilic leukemia (aCML/CNL), or MDS/MPN not otherwise specified (NOS). A total of 101 patients were included (median age 71 years). MDS/MPN SF3B1 -T showed a significant survival advantage compared with MDS/MPN NOS and aCML/CNL (OS p = 0.0058, LFS p = 0.012). aCML/CNL displayed the worst outcomes and most genetic complexity. Across the overall cohort, IPSS-M demonstrated the highest discriminative ability and calibration accuracy for both OS and LFS, outperforming CMML-directed models, including BLAST-clinical and BLAST-molecular whereas disease-specific scores provided optimal stratification within individual entities but failed to adequately predict outcomes in MDS/MPN NOS. In this real-world analysis, IPSS-M emerged as the most robust prognostic framework across MDS/MPN entities other than CMML. The inability of current tools to reliably stratify patients with MDS/MPN NOS underscores the biological heterogeneity of this category and highlights the urgent need for integrated clinical and genomic prognostic models.
- 17 August 2026
- Published by Wiley in British Journal of Haematology
- Vol. 209 (4) , 1913-1917
De novo JAK2 ‐mutated acute myeloid leukaemia: Clinical outcomes and molecular features
- 17 August 2026
- Published by Wiley in British Journal of Haematology
- Vol. 209 (4) , 1913-1917
De novo JAK2 ‐mutated acute myeloid leukaemia: Clinical outcomes and molecular features
- Open Access
- 5 August 2026
- Published by Springer Nature in Leukemia
- Vol. 40 (11) , 2406-2415
Multilineage lymphoid clonal hematopoiesis: a cross-sectional, correlative analysis of plasma cell dyscrasias and large granular lymphocytic leukemia
Clonal expansions in large granular lymphocytic leukemia (LGLL) may arise in response to immune dysregulation in the context of other hematologic malignancies. This study aimed to investigate the co-occurrence of LGLL and plasma cell dyscrasias (PCDs) to assess its prevalence, features, and potential underlying mechanisms. We conducted a cross-sectional study involving 2064 PCD cases and 534 LGLL cases. Of the 534 LGLL cases, 20% co-occurred with PCD, while LGLL was present in 2% of the 2064 PCD cases. Among 117 patients with both conditions, PCDs were predominantly associated with IgM M-protein, while LGLL patients had increased NK-cell proliferation and fewer mutations in STAT3/5B . The co-occurrence was linked to a higher incidence of autoimmune conditions, B-cell neoplasms, and more severe immune-mediated cytopenias. In symptomatic PCD/LGLL patients with low plasma-cell infiltration, B-cell-targeted therapies outperformed immunosuppression, suggesting humoral involvement. Correlation with biological parameters revealed elevated interleukin-6 and inhibitory effects of sera of symptomatic PCD/LGLL patients on hematopoietic cells. Our findings suggest an association between PCD and LGLL, characterized by distinct features that may have significant implications for clinical management. These results highlight the importance of considering hematologic co-occurrences in clinical practice and warrant further investigation into the molecular mechanisms linking these conditions.
- 5 August 2026
- Published by Springer Nature in Leukemia
- Vol. 40 (11) , 2406-2415
Open AccessMultilineage lymphoid clonal hematopoiesis: a cross-sectional, correlative analysis of plasma cell dyscrasias and large granular lymphocytic leukemia
Clonal expansions in large granular lymphocytic leukemia (LGLL) may arise in response to immune dysregulation in the context of other hematologic malignancies. This study aimed to investigate the co-occurrence of LGLL and plasma cell dyscrasias (PCDs) to assess its prevalence, features, and potential underlying mechanisms. We conducted a cross-sectional study involving 2064 PCD cases and 534 LGLL cases. Of the 534 LGLL cases, 20% co-occurred with PCD, while LGLL was present in 2% of the 2064 PCD cases. Among 117 patients with both conditions, PCDs were predominantly associated with IgM M-protein, while LGLL patients had increased NK-cell proliferation and fewer mutations in STAT3/5B . The co-occurrence was linked to a higher incidence of autoimmune conditions, B-cell neoplasms, and more severe immune-mediated cytopenias. In symptomatic PCD/LGLL patients with low plasma-cell infiltration, B-cell-targeted therapies outperformed immunosuppression, suggesting humoral involvement. Correlation with biological parameters revealed elevated interleukin-6 and inhibitory effects of sera of symptomatic PCD/LGLL patients on hematopoietic cells. Our findings suggest an association between PCD and LGLL, characterized by distinct features that may have significant implications for clinical management. These results highlight the importance of considering hematologic co-occurrences in clinical practice and warrant further investigation into the molecular mechanisms linking these conditions.
- Open Access
- 22 July 2026
- Published by Springer Nature in Leukemia
- Vol. 40 (10) , 2332-2336
Molecular and clinical analyses of c-CBL mutations affecting tyrosine 371 in myelodysplastic and proliferative disorders
- 22 July 2026
- Published by Springer Nature in Leukemia
- Vol. 40 (10) , 2332-2336
Open AccessMolecular and clinical analyses of c-CBL mutations affecting tyrosine 371 in myelodysplastic and proliferative disorders
- Open Access
- 8 June 2026
- Published by Springer Nature in Leukemia
- Vol. 40 (7) , 1532-1534
Normal life expectancy after all-trans retinoic acid and arsenic trioxide for acute promyelocytic leukemia
- 8 June 2026
- Published by Springer Nature in Leukemia
- Vol. 40 (7) , 1532-1534
Open AccessNormal life expectancy after all-trans retinoic acid and arsenic trioxide for acute promyelocytic leukemia
- Open Access
- 13 May 2026
- Published by American Society of Hematology in Blood Advances
- Vol. 10 (10) , 3347-3356
Validation of ICC hierarchical classification in secondary AML
Secondary acute myeloid leukemia (AML) comprises heterogeneous entities, unified by poor prognosis. We evaluated the associations of genetic profiles with blast counts and patients’ history in a cohort of 924 patients with myelodysplastic syndrome (MDS)/AML or AML, classified according to the International Consensus Classification (ICC). The cohort included 109 patients with “mutated TP53,” 497 with “myelodysplasia-related (MDR) gene mutation,” 93 with “MDR-cytogenetic abnormality,” 77 were therapy-related, and 136 controls, categorized as “not otherwise specified” (NOS) AML. Exploring the ICC hierarchy, AML and MDS/AML categories with “mutated TP53” and “MDR-cytogenetic abnormality” presented similar biology and prognosis, irrespective of blast counts. Conversely, in MDS/AML with “MDR gene mutation” and NOS, profiles significantly differed from AML and were characterized by a higher number of mutations in STAG2, SRSF2, ASXL1 and TET2. This corresponded to improved survival in MDS/AML vs AML (MDR-gene mutation: median overall survival 24.8 vs 13.6 months, P< .0001; and NOS: 49.9 vs 19.2 months, P = .028). Within each ICC-defined AML category, a prior MDS history vs de novo onset did not impact on patients’ prognosis. We then analyzed secondary AML, defined by “prior MDS or MDS/MPN” or “therapy-related” (t-AML), as diagnostic qualifiers. According to European LeukemiaNet (ELN) 2022, AML progressing from MDS or MDS/myeloproliferative neoplasm (MPN) (AML post-MDS) mostly clustered in the adverse-risk group (84.1%), whereas t-AML showed more heterogeneous ELN profiles (12.9% favorable, 33.8% intermediate, and 53.3% adverse risk) reflecting diverse overall survival. Our findings underscore that genetic features and the ICC classification reliably capture disease biology, refine risk stratification, and ultimately guide treatment decisions in most secondary AML and MDS/AML.
- 13 May 2026
- Published by American Society of Hematology in Blood Advances
- Vol. 10 (10) , 3347-3356
Open AccessValidation of ICC hierarchical classification in secondary AML
Secondary acute myeloid leukemia (AML) comprises heterogeneous entities, unified by poor prognosis. We evaluated the associations of genetic profiles with blast counts and patients’ history in a cohort of 924 patients with myelodysplastic syndrome (MDS)/AML or AML, classified according to the International Consensus Classification (ICC). The cohort included 109 patients with “mutated TP53,” 497 with “myelodysplasia-related (MDR) gene mutation,” 93 with “MDR-cytogenetic abnormality,” 77 were therapy-related, and 136 controls, categorized as “not otherwise specified” (NOS) AML. Exploring the ICC hierarchy, AML and MDS/AML categories with “mutated TP53” and “MDR-cytogenetic abnormality” presented similar biology and prognosis, irrespective of blast counts. Conversely, in MDS/AML with “MDR gene mutation” and NOS, profiles significantly differed from AML and were characterized by a higher number of mutations in STAG2, SRSF2, ASXL1 and TET2. This corresponded to improved survival in MDS/AML vs AML (MDR-gene mutation: median overall survival 24.8 vs 13.6 months, P< .0001; and NOS: 49.9 vs 19.2 months, P = .028). Within each ICC-defined AML category, a prior MDS history vs de novo onset did not impact on patients’ prognosis. We then analyzed secondary AML, defined by “prior MDS or MDS/MPN” or “therapy-related” (t-AML), as diagnostic qualifiers. According to European LeukemiaNet (ELN) 2022, AML progressing from MDS or MDS/myeloproliferative neoplasm (MPN) (AML post-MDS) mostly clustered in the adverse-risk group (84.1%), whereas t-AML showed more heterogeneous ELN profiles (12.9% favorable, 33.8% intermediate, and 53.3% adverse risk) reflecting diverse overall survival. Our findings underscore that genetic features and the ICC classification reliably capture disease biology, refine risk stratification, and ultimately guide treatment decisions in most secondary AML and MDS/AML.
- Open Access
- 8 January 2026
- Published by American Society of Hematology in Blood
- Vol. 147 (2) , 197-208
Telomere content and genomics of myeloid neoplasia by whole-genome sequencing
Telomere length shortening has been associated with genomic instability and acquisition of molecular lesions, but these processes have not been systematically studied across large cohorts of myeloid neoplasia (MN). As proof of concept for a novel, cross-validated whole-genome sequencing–based method of telomere content (TC) determination combined with mutations, transcriptomics, and functional assays, we studied TC in correlation with specific molecular features of a large cohort (N = 1804) of patients with MN, including acute myeloid leukemia (AML) and myelodysplastic syndrome. When compared with healthy participants and patients with nonclonal diseases such as persistent polyclonal B-cell lymphocytosis, both MN and nonmalignant controls with clonal disease, such as paroxysmal nocturnal hemoglobinuria and aplastic anemia, exhibited decreased TC. Furthermore, we show that TC is lowered in adult MN abrogating correlation with age with considerable TC diversification among certain morphologic and molecular subtypes. For instance, AML harbored the lowest TC. Furthermore, MN originating from a more mature cell of origin (eg, acute promyelocytic leukemia) or characterized by hyperproliferative driver mutations (eg, RAS pathway genes) had lower TC, possibly indicating a loss of telomere maintenance capacity. In contrast, compared with other mutations, MN subtypes arising in a context of profound genetic alterations, such as TP53 mutations and complex karyotype, exhibited a relatively higher/preserved TC. This phenomenon did not involve alternative lengthening processes but was rather consistent with an increased TC due to preserved activity of the telomerase complex. Our results describe a common and genotype-specific telomeric makeup of a large cohort of patients with MN providing a molecular benchmark for future therapeutic targeting of the telomere machinery.
- 8 January 2026
- Published by American Society of Hematology in Blood
- Vol. 147 (2) , 197-208
Open AccessTelomere content and genomics of myeloid neoplasia by whole-genome sequencing
Telomere length shortening has been associated with genomic instability and acquisition of molecular lesions, but these processes have not been systematically studied across large cohorts of myeloid neoplasia (MN). As proof of concept for a novel, cross-validated whole-genome sequencing–based method of telomere content (TC) determination combined with mutations, transcriptomics, and functional assays, we studied TC in correlation with specific molecular features of a large cohort (N = 1804) of patients with MN, including acute myeloid leukemia (AML) and myelodysplastic syndrome. When compared with healthy participants and patients with nonclonal diseases such as persistent polyclonal B-cell lymphocytosis, both MN and nonmalignant controls with clonal disease, such as paroxysmal nocturnal hemoglobinuria and aplastic anemia, exhibited decreased TC. Furthermore, we show that TC is lowered in adult MN abrogating correlation with age with considerable TC diversification among certain morphologic and molecular subtypes. For instance, AML harbored the lowest TC. Furthermore, MN originating from a more mature cell of origin (eg, acute promyelocytic leukemia) or characterized by hyperproliferative driver mutations (eg, RAS pathway genes) had lower TC, possibly indicating a loss of telomere maintenance capacity. In contrast, compared with other mutations, MN subtypes arising in a context of profound genetic alterations, such as TP53 mutations and complex karyotype, exhibited a relatively higher/preserved TC. This phenomenon did not involve alternative lengthening processes but was rather consistent with an increased TC due to preserved activity of the telomerase complex. Our results describe a common and genotype-specific telomeric makeup of a large cohort of patients with MN providing a molecular benchmark for future therapeutic targeting of the telomere machinery.
- 30 October 2025
- Published by Elsevier in Current Research in Translational Medicine
- Vol. 73 (4) , 103548
IDH1 mutation in acute lymphoblastic leukemia—A rare but significant finding
- 30 October 2025
- Published by Elsevier in Current Research in Translational Medicine
- Vol. 73 (4) , 103548
IDH1 mutation in acute lymphoblastic leukemia—A rare but significant finding